Diarrhea News and Research

Latest Diarrhea News and Research

FDA approves Clinical Data's Viibryd for major depressive disorder

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD).

24 Jan 2011

Rotavirus vaccine significantly cuts child hospitalizations, study says

Developing and developed countries that require children to be vaccinated against rotavirus "have significantly reduced the number of children admitted to hospitals with the disease, a report showed on Thursday," Reuters reports (Kelland, 1/20).

24 Jan 2011

PGxHealth receives FDA approval for Viibryd tablets to treat major depressive disorder

The U.S. Food and Drug Administration today approved Viibryd tablets (vilazodone hydrochloride) to treat major depressive disorder in adults.

24 Jan 2011

Routine rotavirus vaccine shows a significant drop in diarrhea cases: Study

A latest study has shown that the rotavirus vaccines have helped drastically reduce hospital visits around the world. Rotavirus can lead to fatal cases of diarrhea in children and causes half a million deaths in kids under five each year around the world. Developing countries are particularly at risk.

20 Jan 2011

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

Vertex Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for telaprevir and granted the company's request for six-month Priority Review. Telaprevir is Vertex's lead medicine in development for people with genotype 1 chronic hepatitis C.

20 Jan 2011

Baked goods made from hydrolyzed wheat flour are not toxic to celiac disease patients

Baked goods made from hydrolyzed wheat flour are not toxic to celiac disease patients, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

20 Jan 2011

Legionnaires’ disease scare in Bali: Australian tourists warned

Commonwealth chief medical officer Jim Bishop has warned Australians who have returned from Bali on an outbreak of Legionnaires’ disease on the popular Indonesian resort island. The Australian health authorities knew of 11 cases of Legionnaires’ disease detected in Victorians and Western Australians after holidays in the Kuta area of Bali between August 2010 and January 2011.

19 Jan 2011

Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas

ARIAD Pharmaceuticals, Inc., today announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to placebo in the Phase 3 SUCCEED trial conducted in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.

19 Jan 2011

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Eli Lilly Canada is pleased to announce the Health Canada approval of BYETTATM for the treatment of adults with type 2 diabetes.

18 Jan 2011

Antibiotics need to be used only when diagnosis of acute ear infection is certain

A new study showed that antibiotics are more effective than previously thought in the treatment of acute ear infection (namely acute otitis media) in young children. However, half of the children became better without antibiotics. Expectedly, antibiotics caused more adverse events. Antibiotics should be used only when the diagnosis of acute ear infection is certain.

13 Jan 2011

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a joint collaboration with Synta Pharmaceuticals for the clinical development of ganetespib (formerly STA-9090) in patients with multiple myeloma.

13 Jan 2011

Antibiotics for ear infection in kids better than watchful waiting: Study

Findings from two latest clinical trials reveal that a young child with ear infections recovers faster and more completely if doctors give antibiotics right away rather than waiting to see if the kid get better on his/her own. One of the studies was in the U.S. and one in Finland. Earlier it has been debated that for young children with middle ear infections or otitis media whether immediate antibiotic treatment was better than watchful waiting. Current treatment recommendations in the U.S., Canada, and Europe allow for a watch-and-wait approach to suspected middle ear infections in young children. Change is coming, predicts study leader Alejandro Hoberman, MD, of Children’s Hospital of Pittsburgh.

12 Jan 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Dirty cash machines – Literally!

Experts have found that cash machines carry same amounts and kinds of bacteria as a public toilet. They took swabs from both places and found pseudomonads and bacillus bacteria types, both of which are behind common afflictions such as diarrhea.

11 Jan 2011

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of the 24-week treatment phase of the company's Phase 3 registration study of GATTEX® (teduglutide).

11 Jan 2011

Floods may become a healthcare challenge, warns the AMA

The Australian Medical Association (AMA) has issued warnings to the Queensland health authorities to prepare for the rise of illnesses and injuries caused by the floods.

10 Jan 2011

Tips for surviving a bout with 'stomach flu'

A post-holiday crush of patients are crowding into area physician offices and hospital emergency rooms as individuals of all ages suddenly find themselves laid low by a highly contagious and quick-striking virus.

10 Jan 2011

Synergy's plecanatide Phase II/III trial to begin in second quarter 2011

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to treat chronic idiopathic constipation patients, planned to begin in the second quarter of 2011, has been designed as a Phase II/III trial.

7 Jan 2011

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Bristol-Myers Squibb Company, and AstraZeneca today announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.

7 Jan 2011

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. today announced the dosing of the first patient in the third phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain, excluding those taking methadone. The primary endpoint is an overall responder rate based on the change from baseline in the reported frequency of spontaneous bowel movements (SBMs).

7 Jan 2011

Diarrhea News and Research

Latest Diarrhea News and Research

FDA approves Clinical Data's Viibryd for major depressive disorder

Rotavirus vaccine significantly cuts child hospitalizations, study says

PGxHealth receives FDA approval for Viibryd tablets to treat major depressive disorder

Routine rotavirus vaccine shows a significant drop in diarrhea cases: Study

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

Baked goods made from hydrolyzed wheat flour are not toxic to celiac disease patients

Legionnaires’ disease scare in Bali: Australian tourists warned

Ridaforolimus achieves primary endpoint in Phase 3 trial for metastatic soft-tissue and bone sarcomas

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Antibiotics need to be used only when diagnosis of acute ear infection is certain

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

Antibiotics for ear infection in kids better than watchful waiting: Study

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Dirty cash machines – Literally!

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

Floods may become a healthcare challenge, warns the AMA

Tips for surviving a bout with 'stomach flu'

Synergy's plecanatide Phase II/III trial to begin in second quarter 2011

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in